Core Insights - Co-Diagnostics has signed an agreement to expand its commercial and distribution territory across South Asia, now including Bangladesh, Pakistan, Nepal, and Sri Lanka, which increases the total addressable market (TAM) in the region to $13 billion [1][2]. Market Expansion - The expansion supports CoSara's plans to commercialize the CoSara PCR Pro® point-of-care instrument and the SARAGENE® product line, pending regulatory approvals in each jurisdiction [2]. - CoSara is establishing distribution channels in the newly added markets, focusing on regulatory pathways, priority customer segments, and regional distribution partners [2]. Strategic Goals - The CEO of CoSara highlighted the growing demand for accessible and reliable molecular diagnostics in South Asia, emphasizing the importance of building relationships with regional partners [3]. - Co-Diagnostics' CEO stated that this expansion aligns with the company's strategy to establish regional infrastructure ahead of product commercialization, aiming for scalable global deployment of their PCR platform [3]. Future Engagement - To support the expansion efforts, CoSara plans to host a virtual distributor information session in Q2 2026, followed by an in-person distributor meeting and training event later in the summer [3].

Core Insights - Co-Diagnostics, Inc. has regained compliance with NASDAQ listing requirements and resumed trading on March 11, 2026, enhancing its capital markets position [1] - The company is actively expanding its global presence and intellectual property, participating in Medical Korea 2026 to showcase its Co-Dx PCR point-of-care platform [2] - A new patent granted by the Japan Patent Office supports the Co-Dx PCR Pro® instrument and strengthens the company's international IP protection [3] - As of March 13, 2026, CODX stock closed at $2.80, with a market capitalization of approximately $5.87 million [4] - Co-Diagnostics is positioned as an emerging player in molecular diagnostics, focusing on clinical studies and global expansion [5] Group 1 - Co-Diagnostics has regained compliance with NASDAQ listing requirements and resumed trading on March 11, 2026, confirming compliance with the $1.00 minimum bid price rule [1] - The company will participate in Medical Korea 2026 in Seoul, South Korea, from March 19-22, 2026, showcasing its innovative diagnostic solutions [2] - The Japan Patent Office granted a patent that supports the Co-Dx PCR Pro® instrument, enhancing the company's international IP protection [3] Group 2 - CODX stock closed at $2.80 on March 13, 2026, reflecting a 3.75% increase, with a trading volume of 1,105,301 shares [4] - The company is focusing on clinical studies, regulatory pathways, and global expansion for its point-of-care technologies [5]

Financial Data and Key Metrics Changes - For the full year 2025, the company achieved 100% year-over-year growth with an adjusted EBITDA margin of 13%, a positive GAAP operating margin, and positive cash flow [6][26] - Total revenue in Q4 2025 was $96.1 million, representing a 113% year-over-year increase, driven by rapid increases in tests delivered and ASPs across both product lines [21][29] - Gross profit in Q4 2025 was $68.6 million, resulting in a gross margin of 71.4%, compared to 57% in Q4 2024 [31] Business Line Data and Key Metrics Changes - Prenatal revenue in Q4 was $86.9 million, up 98% year-over-year, reaching an annualized run rate of $348 million [21][29] - Oncology revenue reached $9.1 million in Q4, achieving a 736% year-over-year increase, driven by increasing adoption of both Select and Response [22][29] - The number of tests delivered in 2025 grew 51% to 610,000, with overall ASP increasing 35% to $495 [33] Market Data and Key Metrics Changes - The company achieved a gross margin profile above 70%, despite subscale ASPs, particularly in oncology [11] - The overall ASP increased another 12% quarter-over-quarter from $501 to $561, reflecting several converging tailwinds [23] Company Strategy and Development Direction - The long-term goal remains to build a category-defining business and enter the S&P 500, with a focus on continuous improvement and operational efficiency [11][42] - The company is positioned to address more than $100 billion in U.S. market opportunity over time, leveraging its revolutionary technology platform [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong momentum in both prenatal and oncology segments, and the potential for further ASP expansion [37][40] - The recent contract with UnitedHealthcare is expected to enhance ASPs and reduce friction in patient access to tests [60] Other Important Information - The company ended the year with approximately $496 million in cash and equivalents and just $50 million in term debt, positioning it for strong growth moving forward [34] - The company achieved GAAP profitability in both Q4 2025 and full year 2025, with significant improvements in net margin and operating margin [26][34] Q&A Session Summary Question: Awareness of UNITY among providers - Management noted that around 50% of providers do not know about UNITY, indicating significant growth potential as awareness increases [46][47] Question: Conversations with MFMs regarding test uptake - MFMs are crucial decision-makers for high-risk pregnancies, and their advocacy for UNITY can significantly influence OBs' test choices [49][50] Question: New provider metrics for Northstar - The company reported a significant increase in active ordering providers in Q4, indicating strong growth potential for Q1 [54][55] Question: Gross margin expectations - Management expects gross margins to remain in the high 60% range, with potential for slight fluctuations based on product mix [57] Question: Impact of UnitedHealthcare contract - The in-network contract is expected to lead to higher ASPs, as previous contracts have not resulted in ASP decreases [60][61] Question: Competitive landscape and market impact - Management indicated that they have not seen significant impact from competitors, as evidenced by strong test volume growth and increased prenatal revenues [64]

Financial Data and Key Metrics Changes - For the full year 2025, the company achieved 100% year-over-year growth with an adjusted EBITDA margin of 13%, a positive GAAP operating margin, and positive cash flow [6][26] - Total revenue in Q4 2025 was $96.1 million, representing a 113% year-over-year increase, with prenatal revenue at $86.9 million (up 98%) and oncology revenue at $9.1 million (up 736%) [29][21] - Gross margins improved to 71.4% in Q4 2025, a 14.3 percentage point increase year-over-year [25][31] Business Line Data and Key Metrics Changes - Test volumes grew by 51% year-over-year, reaching approximately 170,000 tests in Q4 2025 [20][33] - The average selling price (ASP) increased by 35% year-over-year to $495 for the full year 2025, with a significant sequential increase of $60 per test in Q4 [23][34] - Oncology revenue growth was driven by the adoption of Northstar Select and Response, with a quarter-over-quarter growth of 29% excluding true-up revenue [22][30] Market Data and Key Metrics Changes - The company reached an annualized revenue run rate of $384 million in Q4 2025, indicating strong market demand and growth potential [10][21] - The company has secured Medicare coverage for Northstar Select and signed contracts covering over 250 million lives in the U.S. [8][10] Company Strategy and Development Direction - The company aims to build a category-defining business and enter the S&P 500, focusing on innovation in prenatal and oncology diagnostics [11][46] - The launch of new products, including expanded fetal antigen NIPT and Northstar Select PGx, is expected to drive future growth [12][40] - The company emphasizes operational efficiency and cost reduction, achieving GAAP profitability while maintaining high growth rates [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, citing strong test volume momentum and the impact of new clinical guidelines on market adoption [37][38] - The company anticipates that the recent contract with UnitedHealthcare will enhance ASPs and reduce friction in patient access to tests [42][63] - Management believes that the current guidance for 2026 is conservative, with several growth drivers not fully reflected in the projections [35][79] Other Important Information - The company ended 2025 with approximately $496 million in cash and only $50 million in term debt, positioning it well for future growth [34][35] - The company achieved a significant milestone by going public during a challenging market environment, demonstrating resilience and execution capability [5][6] Q&A Session Summary Question: Awareness of UNITY among providers - Management noted that around 50% of providers are unaware of UNITY, indicating significant growth potential as awareness increases [49][50] Question: Conversations with health systems regarding MFMs - Management highlighted the importance of MFMs in driving test adoption and the ongoing discussions to increase uptake among larger health systems [52][53] Question: New provider metrics for Northstar - Management reported a record increase in active ordering providers in Q4, signaling strong growth potential for Q1 2026 [56][58] Question: Gross margin expectations - Management indicated that gross margins are expected to remain stable in the high 60% to low 70% range, without aggressive expectations for expansion [60] Question: Impact of UnitedHealthcare contract - Management expects higher ASPs from the in-network contract with UnitedHealthcare, which covers both prenatal and oncology products [63][65] Question: Competitive landscape and impact from Natera - Management stated that they have not seen any negative impact from competition, as evidenced by strong test volume growth and increased prenatal revenues [68]

Financial Data and Key Metrics Changes - For the full year 2025, the company achieved 100% year-over-year growth with an adjusted EBITDA margin of 13%, a positive GAAP operating margin, and positive cash flow [5][34] - Total revenue in Q4 2025 was $96.1 million, representing an increase of 113% compared to $45.1 million in Q4 2024 [29][30] - Gross profit in Q4 2025 was $68.6 million, resulting in a gross margin of 71.4%, up from 57% in Q4 2024 [31][34] - The overall ASP increased from $368 in 2024 to $495 in 2025, a 35% year-over-year increase [33][24] Business Line Data and Key Metrics Changes - Prenatal revenue in Q4 was $86.9 million, up 98% year-over-year, reaching an annualized run rate of $348 million [21][29] - Oncology revenue reached $9.1 million in Q4, achieving a 736% year-over-year increase, with an annualized revenue run rate of $36 million [23][29] - Test volumes grew by 51% year-over-year, with approximately 170,000 tests delivered in Q4 [20][33] Market Data and Key Metrics Changes - The company signed 44 payer contracts, adding more than 25 million lives, reaching a total of 250 million contracted lives in the U.S. [6] - The company achieved a gross margin profile above 70%, despite subscale ASPs, particularly in oncology [10] Company Strategy and Development Direction - The long-term goal remains to build a category-defining business and enter the S&P 500 [10] - The company is focused on expanding its prenatal and oncology product lines, with recent launches aimed at solidifying its competitive advantage [11][18] - The company aims to leverage its revolutionary technology platform to address a market opportunity exceeding $100 billion in the U.S. [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong performance across all teams and the potential for further market penetration [4][7] - The company anticipates continued momentum in both prenatal and oncology segments, driven by new product launches and increased awareness among healthcare providers [37][41] - Management highlighted the importance of the recent in-network contract with UnitedHealthcare, which is expected to enhance ASPs and reduce friction in patient access to tests [41][60] Other Important Information - The company ended the year with approximately $496 million in cash and equivalents and only $50 million in term debt, positioning it for strong growth moving forward [34][35] - The company achieved GAAP profitability in both Q4 2025 and the full year 2025, with significant improvements in net and operating margins [27][34] Q&A Session Summary Question: Awareness of UNITY among providers - Management noted that around 50% of providers are unaware of UNITY, indicating significant growth potential as awareness increases [47][48] Question: Conversations with MFMs regarding test uptake - Management emphasized the influence of MFMs on test selection and the importance of building relationships with them to drive adoption [50][51] Question: New provider metrics for Northstar - Management reported a record increase in active ordering providers, indicating strong growth potential for Q1 2026 [54][55] Question: Gross margin expectations - Management expects gross margins to remain stable in the high 60% range, with no aggressive expectations for expansion [56] Question: Impact of UnitedHealthcare contract - Management anticipates higher ASPs from the in-network contract with UnitedHealthcare, which is expected to streamline reimbursement processes [60][61] Question: Coverage discussions with CMS - Management is in discussions with CMS regarding coverage for Northstar Response, with expectations for a decision by the end of the year [78]

Core Insights - BillionToOne, Inc. reported significant financial growth in Q4 2025 and raised its revenue guidance for 2026, reflecting strong demand for its molecular diagnostics products [1][4]. Financial Highlights - Total revenue for Q4 2025 was $96.1 million, a 113% increase from $45.1 million in Q4 2024 [5][7]. - Prenatal testing revenue reached $86.1 million in Q4 2025, up 99% from $43.2 million in Q4 2024 [5][11]. - Oncology testing revenue surged to $9.1 million in Q4 2025, an increase of 735% from $1.1 million in Q4 2024 [5][11]. - Gross profit margin improved to 71% in Q4 2025, compared to 57% in Q4 2024, driven by higher average selling prices (ASP) and reduced costs [8][12]. - Operating income was $10.3 million in Q4 2025, reversing an operating loss of $11.7 million in Q4 2024 [9][10]. Recent Operating Highlights - The company delivered 170,000 tests in Q4 2025, a 47% increase from 116,000 tests in Q4 2024 [5][6]. - BillionToOne launched new prenatal and oncology products in early 2026, including non-invasive prenatal tests for fetal antigen status and expanded applications for its Northstar platform [5][14]. - The company expects full-year 2026 revenue to be between $430 million and $445 million, representing a growth of 41% to 46% compared to 2025 [14]. Full Year 2025 Financial Results - Total revenue for 2025 was $305.1 million, a 100% increase from $152.6 million in 2024 [11][12]. - Gross profit for 2025 was $208.5 million, with a gross margin of 68%, up from 53% in 2024 [12][13]. - Net income available to common shareholders for 2025 was $2.9 million, or $0.14 per diluted share, compared to a net loss of $41.6 million in 2024 [13]. Cash Position - As of December 31, 2025, BillionToOne held approximately $496.0 million in cash and cash equivalents, indicating a strong liquidity position [13][22].

Core Viewpoint - Qiagen N.V. is reviewing strategic options, including a potential sale, due to renewed takeover interest and has engaged advisers for evaluation [1][2] Group 1: Strategic Review and Potential Sale - Qiagen has held preliminary talks with multiple interested parties, including U.S.-based strategic buyers, although there is no certainty of a transaction [2] - The departure of CEO Thierry Bernard, expected once a successor is appointed, is seen as removing a key obstacle to a potential deal, making Qiagen more attractive to buyers [3] Group 2: Historical Acquisition Attempts - Qiagen has faced acquisition interest multiple times in recent years, but previous efforts did not result in a sale [4] - Notable past interest includes a high-profile approach from Thermo Fisher Scientific in 2020, which was valued at approximately $12 billion but collapsed due to opposition from an activist investor [5] - In 2021, Qiagen explored a potential combination with BioMérieux, which also did not materialize, and in 2022, discussions were reported with Bio-Rad Laboratories [6] Group 3: Financial Performance - For the third quarter, Qiagen reported adjusted earnings of 61 cents, exceeding the consensus of 59 cents, with sales of $533 million above the consensus of $525.93 million [7] - The company raised its fiscal adjusted earnings per share guidance from $2.35 to $2.38, compared to the consensus of $2.37, while affirming its sales guidance of $2.057 billion to $2.077 billion against a consensus of $2.082 billion [7] - Qiagen expects fourth-quarter adjusted earnings of 60 cents, slightly below the consensus of 61 cents per share [8] Group 4: Recent Acquisition Activity - In November 2025, Qiagen agreed to acquire Parse Biosciences for an upfront payment of approximately $225 million, with additional potential milestone payments [8] Group 5: Stock Performance - Qiagen shares experienced a decline of 4.09% to $53.18 during premarket trading, following a 16.57% increase to $55.45 the previous day [9]

Core Insights - BillionToOne, Inc. has announced a collaboration with Epic to integrate its prenatal and oncology testing portfolio with Epic's Aura diagnostics suite, enhancing the patient and provider experience [1][2][3] Company Overview - BillionToOne is a next-generation molecular diagnostics company based in Menlo Park, California, focused on creating accessible and accurate tests [5] - The company utilizes a patented Quantitative Counting Templates™ (QCT™) molecular counting platform, which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [5] Integration Details - The integration allows clinicians to order BillionToOne's UNITY Complete® prenatal test and Northstar Select® and Northstar Response® liquid biopsy tests directly within Epic's EHR [2][4] - Test results will flow back into the electronic health record, facilitating clinical decision support and improving the experience for patients and providers across various healthcare settings [2][4] Clinical Impact - UNITY Complete is the first clinically validated non-invasive prenatal test that provides direct fetal risk assessment for multiple conditions from a single maternal blood sample [3] - Northstar Select assists in identifying appropriate therapies for advanced cancer patients, while Northstar Response enables ongoing treatment monitoring [3] User Experience Enhancement - Results will be delivered directly into Epic and accessible through the MyChart patient portal, promoting faster clinical decision-making and a more connected patient experience [4]

JPM Healthcare Conference 2026 Redefining Molecular Diagnostics with Single-Molecule Precision 2 Disclaimer & Forward Looking Statement 2025 Q3 Business Update This presentation contains certain "forward-looking statementsˮ within the meaning of applicable securities laws. These statements relate to future events and results of BillionToOne, Inc. (the "Company,ˮ "we,ˮ "us,ˮ or "ourˮ) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, p ...

Core Viewpoint - BillionToOne, Inc. has reiterated its full year 2025 revenue guidance of $293 million to $299 million and has initiated its full year 2026 guidance, projecting total revenue of $415 million to $430 million, indicating a growth of 40% to 45% compared to the midpoint of the 2025 guidance [1][4]. Group 1: Financial Guidance - The company expects full year 2026 revenue to be between $415 million and $430 million [4]. - This represents a growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range [4]. - The company anticipates positive GAAP operating income for the full year 2026 [4]. Group 2: Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [2]. - The company utilizes a patented Quantitative Counting Templates™ (QCT™) molecular counting platform, which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [2]. Group 3: Leadership Perspective - Dr. Oguzhan Atay, Co-founder and CEO, expressed excitement about the opportunity to scale the company's differentiated platform and emphasized a clear roadmap to address significant clinical challenges [2].